Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a global insulin delivery and diabetes technology company whose news flow centers on product innovation, regulatory milestones, financial performance, and corporate developments. The company manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ or Control-IQ+ hybrid closed-loop technology.
News updates for Tandem Diabetes Care often highlight regulatory and product announcements. Recent examples include FDA 510(k) clearance for the SteadiSet infusion set for up to seven days of use, FDA clearance for the Android version of the Tandem Mobi mobile app, and integration of the t:slim X2 pump with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the United States. The company also issues press releases on software and mobile app availability, such as the Tandem t:slim mobile app launch for Android and iOS users in Canada.
Investors and observers can also expect regular earnings and guidance updates. Tandem Diabetes Care reports quarterly financial results and provides full-year guidance, with related press releases and conference call details disclosed publicly. Additional news items cover corporate governance, such as the appointment of new board members and committee assignments, as well as certifications like ISO/IEC 27001:2022 for information security.
This news page for TNDM aggregates these types of announcements, including earnings releases, regulatory clearances, product compatibility updates, conference presentations, and technology rollouts. It provides a single location to follow how Tandem Diabetes Care’s insulin delivery systems, digital platforms, and global initiatives are evolving over time.
Tandem Diabetes Care (NASDAQ:TNDM) presented positive real-world data from the Control-IQ Observational study at the American Diabetes Association's 82nd Scientific Sessions in New Orleans. The data revealed significant improvements in diabetes management among a diverse cohort using the t:slim X2 insulin pump with Control-IQ technology. Highlights include enhanced quality of life, significant glycemic improvements across various ethnic groups, and demonstrated benefits regardless of prior therapy. The findings emphasize Tandem's commitment to advancing diabetes technology for all patients.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will present a company update at the Piper Sandler Virtual Diabetes Symposium on Wednesday, May 25, 2022, at 11:00 AM ET. The presentation will be webcast live and archived for 30 days on their Investor Center website.
Tandem, based in San Diego, California, specializes in insulin delivery and diabetes technology, offering innovative products like the t:slim X2 insulin pump with Control-IQ technology.
Tandem Diabetes Care, Inc. (TNDM) reported Q1 2022 financial results, with sales rising by 25% to $175.9 million. Worldwide pump shipments increased by 11% to 28,095 units. Cash and equivalents reached $635.4 million, up $11.6 million this quarter. The company updated its 2022 guidance, estimating sales between $850 million and $865 million, reflecting a growth of 21% to 23%. Gross margins are projected at 54%. However, the operating loss increased to $15.3 million, and net loss reached $14.7 million, indicating challenges amidst growth.
Tandem Diabetes Care (NASDAQ:TNDM) announced positive real-world data for its t:slim X2 insulin pump with Control-IQ technology at the 15th International Conference on Advanced Technologies and Treatments for Diabetes in Barcelona. Results from the Control-IQ Observational study showed improvements in glycemic control and quality of life for 1,913 participants. Additionally, 95% of users transitioning from multiple daily injections successfully initiated Control-IQ technology within 14 days. The data emphasizes the technology's effectiveness across various age groups and prior delivery methods.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its first quarter 2022 financial results on May 4, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET (1:30 PM PT) to discuss the outcomes. Investors can dial in using (855) 427-4396 for toll-free and (484) 756-4261 for international access, with the conference ID being 2354706. An archived version of the webcast will be available for 30 days post-event on their Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced a company update presentation scheduled for March 15, 2022, at 10:00 AM Eastern Time during the Oppenheimer 32nd Annual Healthcare Conference. The event will be webcast live, with an archive available for 30 days afterward. Interested parties can access the webcast link via Tandem's Investor Center website. Tandem specializes in innovative insulin delivery systems, including the t:slim X2 insulin pump, designed to enhance the lives of individuals with diabetes.
Tandem Diabetes Care reported robust financial performance for 2021, achieving a 41% increase in sales to $702.8 million. Worldwide pump shipments rose by 41% to 128,312 pumps, with a gross margin of 54%. The company posted a net income of $15.6 million, a turnaround from a $34.4 million loss in 2020. For 2022, Tandem projects sales between $845 million and $860 million, indicating 20% to 22% annual growth. The guidance supports continued investment in innovation and operational improvements.
Tandem Diabetes Care announces FDA clearance for the t:connect mobile app, the first smartphone application allowing bolus insulin delivery via both iOS and Android. This update provides users of the t:slim X2 insulin pump the convenience of programming and canceling bolus requests using their smartphones. Available for free as a software update to existing users, the feature will roll out in limited phases starting in spring. The app enhances diabetes management by displaying glucose trends and pump data securely.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will provide an update at two virtual investor conferences. The first is Citi’s 2022 Virtual Healthcare Conference on February 24, 2022, at 11:00am ET, followed by Cowen's 42nd Annual Health Care Conference on March 9, 2022, at 2:50pm ET. Both presentations will be webcast live, with archives available for 30 days on Tandem's Investor Center website. Tandem is focused on enhancing diabetes care through innovative products like the t:slim X2 insulin pump, which features remote software updates and integrated continuous glucose monitoring.
Tandem Diabetes Care (NASDAQ: TNDM) will announce its fourth quarter and full year 2021 results on February 22, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the financial and operational highlights. Interested parties can join the call at (855) 427-4396 (toll-free) or (484) 756-4261 (international). An archived version of the webcast will be available for 30 days on their Investor Center website.